Skip to main content

Table 6 Types of immunosuppressants of flare and non-flare group in SACQ and SQCQ patients

From: Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study

 

SACQ (170)

SQCQ (187)

Flare (23/56)

Non-flare (69/114)

p

Flare (10/29)

Non-flare (87/158)

p

AZA

12/23 (52.5%)

27/69 (39.1%)

0.273

2/10 (20%)

23/87 (26.4%)

0.659

MMF

5/23 (21.7%)

23/69 (33.3%)

0.295

1/10 (10%)

21/87 (24.1%)

0.540

MTX

3/23 (13.0%)

11/69 (15.9%)

1.000

6/10 (60%)

23/87 (26.4%)

0.067

LEF

2/23 (8.7%)

8/69 (11.6%)

1.000

5/10 (50%)

20/87 (23.0%)

0.142

CTX

3/23 (13.0%)

4/69 (5.8%)

0.496

2/10 (20%)

6/87 (6.9%)

0.412

CSA

3/23 (13.0%)

1/69 (1.4%)

0.077

0/10 (0%)

4/87 (4.6%)

1.000

  1. AZA azathioprine, MMF mycophenolate mofetil, MTX methotrexate, LEF leflunomide, CTX cyclophosphamide, CsA cyclosporin A